ZCA
RCKT icon

Zeke Capital Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Zeke Capital Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-18,326
Closed -$417K – 453
2019
Q4 		$417K Hold
18,326
– – 0.03% 415
2019
Q3 		$213K Buy
18,326
+8,094
+79% +$100K 0.02% 524
2019
Q2 		$153K Buy
+10,232
New +$179K 0.01% 557

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Zeke Capital Advisors's RCKT Position: Q1 2020 in Review

Zeke Capital Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q1 2020, closing a stake of 18,326 shares — an estimated $417K sold.

Zeke Capital Advisors first reported a position in RCKT in Q2 2019 and held it in 3 quarters. The position peaked at $417K in Q4 2019. 107 funds tracked by Wall St. Rank hold RCKT as of Q1 2020.

  • Zeke Capital Advisors reported no remaining Rocket Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Zeke Capital Advisors sold 18,326 Rocket Pharmaceuticals shares in Q1 2020, an estimated $417K.
  • Zeke Capital Advisors first reported a position in Rocket Pharmaceuticals in Q2 2019 and held it in 3 quarters.
  • Zeke Capital Advisors's Rocket Pharmaceuticals position peaked at $417K in Q4 2019.
  • 107 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2020.

Based on Zeke Capital Advisors's 13F filing for Q1 2020, filed 24 Apr 2020.